Investor Meeting is Potential Catalyst for Teva (TEVA)

Ahead of the company's analyst day on Tuesday, December 11th, Canaccord Genuity maintained a Buy rating on Teva Pharma (NYSE: TEVA) with a price target of $50.00. While analysts don't expect a big stock-moving event, a sentiment shift could be in the works.

"We don't expect any specific stock moving disclosures to come out of the day, nor do we think expectations are for such, but additional revenue transparency combined with the multi-year cost-cutting story introduced a week ago would set TEVA up for a continued rally," said analyst Randall Stanicky.

He thinks TEVA trades at a 34 percent discount to its peers, and sees plenty of upside in the stock.

For an analyst ratings summary and ratings history on Teva Pharma (NYSE: TEVA click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $42.42 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• RBC Capital Upgrades Legrand SA (LR:FP) (LGRDY) to Outperform
• Jefferies Downgrades Muthoot Finance Ltd (MUTH:IN) to Hold
• Jefferies Downgrades Severn Trent Plc. (SVT:LN) (SVTRF) to Hold